NeuBase Therapeutics (NBSE) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Biodegradable Climate Change Contaminant Dump Environment Environmental Environmental Protection Materials Nature Nuclear Offset Package Packaging Pandemic Raw Materials Regeneration Toxic Waste Water Access African American Asian Attrition Benefits Black Collective Bargaining Community Culture Customer Cyber Cybersecurity Death Disability Diversity Drug Pricing Employee Engagement Gender Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Human Rights Incident Latinx Minority Privacy Product Safety Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skilled Skills Social Society Supplier Supply Chain Talent Training Union Volunteer Workforce Assessment Assurance Attorneys General Audit Board Oversight Bonus Bribery Chronic Class Action Lawsuit Classified Classified Board Commitment Conflict of Interest Corporate Governance Corporate Purpose Department of ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigant Litigation Long-term Majority Materiality Mission Oversee Oversight Plaintiff Pledging Purpose Quality Standard R&D Reputation Research and Development Responsibility Responsible Special Meeting Strategy Sustainability Sustainable Targets Tax Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On September 8, 2022, NeuBase Therapeutics, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”). A total of 19,803,119 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), or 61.39% of the Common Stock issued and outstanding as of the record date for the 2022 Annual Meeting, were represented virtually or by proxy at the 2022 Annual Meeting.

At the 2022 Annual Meeting, the Company’s stockholders considered four proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on July 22, 2022.

Set forth below is a brief description of each matter voted upon at the 2022 Annual Meeting and the voting results with respect to each matter.

Proposal No. 1: To elect two Class II directors, Dietrich A. Stephan, Ph.D. and Gerry J. McDougall, nominated by our Board of Directors (the "Board"), to serve until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified:

Nominee			For				Withheld				Broker Non-Votes
Dietrich A. Stephan, Ph.D.				12,652,094				828,599				6,322,426
Gerry J. McDougall				11,449,267				2,031,426				6,322,426

Proposal No. 2: To ratify the selection of Marcum LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2022.

For				Against				Abstentions
	19,713,132				83,774				6,213

Proposal No. 3: To approve, on an advisory basis, the compensation paid to the Company’s Named Executive Officers, as disclosed pursuant to